| http://www.w3.org/ns/prov#value | - Finally, possible ADE of infection mechanisms should be evaluated before considering a mAb as a possible candidate therapeutic in a post-exposure setting as well as in the development of new Ab-eliciting immunogens.Conflict of InterestsThe authors declare no conflict of interests, in particular, with OmriGam and any other cited Ab-based preparation mentioned in the paper.References
|
